title: Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
authors.affiliation: Department of General Psychiatry, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Kasper
authors.forename: A
authors.initials: A
authors.lastname: Hale
authors.forename: J M
authors.initials: JM
authors.lastname: Azorin
authors.forename: H J
authors.initials: HJ
authors.lastname: Möller
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001569:Benzodiazepines; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018570:Risk Assessment; D018967:Risperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D007093:Imidazoles; D007211:Indoles; D001569:Benzodiazepines; D010890:Pirenzepine; C066304:sertindole; D018967:Risperidone; D000077152:Olanzapine